Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlycoMimetics Inc (NASDAQ:GLYC)

13.89
Delayed Data
As of May 25
 -0.11 / -0.79%
Today’s Change
3.82
Today|||52-Week Range
16.94
+127.70%
Year-to-Date
Shark Bites: There Wasn't Even a Dip to Buy
May 23 / TheStreet.com - Paid Partner Content
Here's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today
May 18 / Zacks.com - Paid Partner Content
GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7%
May 19 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close14.00
Today’s open15.76
Day’s range13.75 - 16.94
Volume14,282,991
Average volume (3 months)1,417,086
Market cap$326.5M
Dividend yield--
Data as of 3:59pm ET, 05/25/2017

Growth & Valuation

Earnings growth (last year)-123.88%
Earnings growth (this year)+5.00%
Earnings growth (next 5 years)--
Revenue growth (last year)-99.91%
P/E ratioNM
Price/Sales7,008.84
Price/Book8.73

Competitors

 Today’s
change
Today’s
% change
IDRAIdera Pharmaceutical...-0.01-0.60%
COLLCollegium Pharmaceut...-0.18-1.93%
NBRVNabriva Therapeutics...+0.10+1.00%
MTNBMatinas BioPharma Ho...-0.01-0.33%
Data as of 4:02pm ET, 05/25/2017

Financials

Next reporting dateAugust 4, 2017
EPS forecast (this quarter)-$0.35
Annual revenue (last year)$18.5K
Annual profit (last year)-$31.8M
Net profit margin-171,945.07%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Rachel K. King
Chief Financial Officer
Brian M. Hahn
Corporate headquarters
Rockville, Maryland

Forecasts